- Previous Close
1,019.50 - Open
1,020.50 - Bid --
- Ask --
- Day's Range
1,019.55 - 1,035.50 - 52 Week Range
710.25 - 1,303.90 - Volume
111,054 - Avg. Volume
280,347 - Market Cap (intraday)
202.42B - Beta (5Y Monthly) 0.69
- PE Ratio (TTM)
31.25 - EPS (TTM)
32.90 - Earnings Date Feb 3, 2025 - Feb 7, 2025
- Forward Dividend & Yield 11.00 (1.07%)
- Ex-Dividend Date Jul 15, 2024
- 1y Target Est
1,138.42
Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. The company was founded in 1907 and is headquartered in Vadodara, India.
alembicpharmaceuticals.com14,858
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: APLLTD.NS
View MorePerformance Overview: APLLTD.NS
Trailing total returns as of 11/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: APLLTD.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: APLLTD.NS
View MoreValuation Measures
Market Cap
202.42B
Enterprise Value
211.59B
Trailing P/E
31.26
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.24
Price/Book (mrq)
4.13
Enterprise Value/Revenue
3.39
Enterprise Value/EBITDA
20.32
Financial Highlights
Profitability and Income Statement
Profit Margin
10.17%
Return on Assets (ttm)
6.61%
Return on Equity (ttm)
13.81%
Revenue (ttm)
63.57B
Net Income Avi to Common (ttm)
6.47B
Diluted EPS (ttm)
32.90
Balance Sheet and Cash Flow
Total Cash (mrq)
1.29B
Total Debt/Equity (mrq)
21.82%
Levered Free Cash Flow (ttm)
-1.3B